Plasma fractalkine is a sustained marker of disease severity and outcome in sepsis patients

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Hoogendijk, Arie J ^a   Wiewel, Maryse A ^a   van Vught, Lonneke A ^a   Scicluna, Brendon P ^a   Belkasim Bohoudi, Hakima ^a   Horn, Janneke ^a   Zwinderman, Aeilko H ^a   Klein Klouwenberg, Peter M C ^b   Cremer, Olaf L ^b   Bonten, Marc J ^b   Schultz, Marcus J ^a   van der Poll, Tom ^a   Frencken, Jos F ^b   Glas, Gerie J ^a   van Hooijdonk, Roosmarijn T M ^a   Huson, Mischa A ^a   Ong, David S Y ^b   Schouten, Laura R A ^a   Straat, Marleen ^a   Witteveen, Esther ^a   Wieske, Luuk ^a   de Beer, Friso M ^a   Bos, Lieuwe D J ^a   more..

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FRACTALKINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; BIOLOGICAL MARKER;

ABDOMINAL INFECTION; ADULT; APACHE; ARTICLE; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL PREDICTION; SURVIVAL TIME; URINARY TRACT INFECTION; YOUDEN INDEX; AGED; BLOOD; INTENSIVE CARE UNIT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; BIOMARKERS; CHEMOKINE CX3CL1; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 84947914808     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-1125-0     Document Type: Article

References (46)

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840-51.
2. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5:4-11.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10.
4. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-4.
5. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113:963-72.
6. Corcione A, Ferretti E, Pistoia V. CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. J Leukoc Biol. 2012;92:51-8.
7. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 2001;276:37993-8001.
8. Miksa M, Amin D, Wu R, Ravikumar TS, Wang P. Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages. Mol Med. 2007;13:553-60.
9. Schulz C, Schafer A, Stolla M, Kerstan S, Lorenz M, von Bruhl ML, et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation. 2007;116:764-73.
10. Ferretti E, Pistoia V, Corcione A. Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies. Mediators Inflamm. 2014;2014:480941.
11. Jones BA, Beamer M, Ahmed S. Fractalkine/CX3CL1: a potential new target for inflammatory diseases. Mol Interv. 2010;10:263-70.
12. D'Haese JG, Friess H, Ceyhan GO. Therapeutic potential of the chemokine-receptor duo fractalkine/CX3CR1: an update. Expert Opin Ther Targets. 2012;16:613-8.
13. Ishida Y, Hayashi T, Goto T, Kimura A, Akimoto S, Mukaida N, et al. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol. 2008;181:4208-18.
14. He M, Moochhala SM, Adhikari S, Bhatia M. Administration of exogenous fractalkine, a CX3C chemokine, is capable of modulating inflammatory response in cecal ligation and puncture-induced sepsis. Shock. 2009;31:33-9.
15. Raspé C, Höcherl K, Rath S, Sauvant C, Bucher M. NF-κB-mediated inverse regulation of fractalkine and CX3CR1 during CLP-induced sepsis. Cytokine. 2013;61:97-103.
16. Pachot A, Cazalis MA, Venet F, Turrel F, Faudot C, Voirin N, et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol. 2008;180:6421-9.
17. Klein Klouwenberg PM, Ong DS, Bos LD, de Beer FM, van Hooijdonk RT, Huson MA, et al. Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med. 2013;41:2373-8.
18. Klein Klouwenberg PM, van Mourik MS, Ong DS, Horn J, Schultz MJ, Cremer OL, et al. Electronic implementation of a novel surveillance paradigm for ventilator-associated events. Feasibility and validation. Am J Respir Crit Care Med. 2014;189:947-55.
19. Scicluna BP, Klein Klouwenberg PM, van Vught LA, Wiewel MA, Ong DS, Zwinderman AH, et al. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. Am J Respir Crit Care Med. 2015;192:826-35.
20. Bos LD, Cremer OL, Ong DS, Caser EB, Barbas CS, Villar J, et al. External validation confirms the legitimacy of a new clinical classification of ARDS for predicting outcome. Intensive Care Med. 2015;41(11):2004-5.
21. Ong DS, Bonten MJ, Safdari K, Spitoni C, Frencken JF, Witteveen E, et al. Epidemiology, management, and risk-adjusted mortality of ICU-acquired enterococcal bacteremia. Clin Infect Dis. 2015;61:1413-20.
22. Ong DS, Klein Klouwenberg PM, Verduyn Lunel FM, Spitoni C, Frencken JF, Dekker HA, et al. Cytomegalovirus seroprevalence as a risk factor for poor outcome in acute respiratory distress syndrome. Crit Care Med. 2015;43:394-400.
23. Geboers DG, de Beer FM, Tuip-de Boer AM, van der Poll T, Horn J, Cremer OL, et al. Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients. Intensive Care Med. 2015;41:1281-90.
24. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308-16.
25. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-40.
26. Calandra T, Cohen J. The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit. Crit Care Med. 2005;33:1538-48.
27. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250-6.
28. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-72.
29. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.
30. Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, et al. NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol. 2000;67:577-84.
31. Sung MJ, Kim W, Ahn SY, Cho CH, Koh GY, Moon SO, et al. Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression. Circ Res. 2005;97:880-90.
32. Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence. 2013;4:507-16.
33. Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med. 2015;277:277-93.
34. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol. 1993;150:644-54.
35. Cummings CJ, Sessler CN, Beall LD, Fisher BJ, Best AM, Fowler 3rd AA. Soluble E-selectin levels in sepsis and critical illness. Correlation with infection and hemodynamic dysfunction. Am J Respir Crit Care Med. 1997;156:431-7.
36. Telen MJ. Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors. Hematol Oncol Clin North Am. 2014;28:341-54.
37. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995;9:899-909.
38. Garton KJ, Gough PJ, Raines EW. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol. 2006;79:1105-16.
39. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A. The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol. 2012;91:472-85.
40. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426-35.
41. Flierl U, Schafer A. Fractalkine - a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost. 2012;108:457-63.
42. Stolla M, Pelisek J, von Bruhl ML, Schafer A, Barocke V, Heider P, et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One. 2012;7, e43572.
43. Staumont-Salle D, Fleury S, Lazzari A, Molendi-Coste O, Hornez N, Lavogiez C, et al. CX(3)CL1 (fractalkine) and its receptor CX(3)CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin. J Exp Med. 2014;211:1185-96.
44. Ridderstad Wollberg A, Ericsson-Dahlstrand A, Jureus A, Ekerot P, Simon S, Nilsson M, et al. Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. Proc Natl Acad Sci USA. 2014;111:5409-14.
45. Huo LW, Ye YL, Wang GW, Ye YG. Fractalkine (CX3CL1): A biomarker reflecting symptomatic severity in patients with knee osteoarthritis. J Investig Med. 2015;63:1-6.
46. Casserly B, Read R, Levy MM. Multimarker panels in sepsis. Crit Care Clin. 2011;27:391-405.